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Background: Bisphosphonate-related osteonecrosis of the jaw is a pathological condition without effective estab-
lished treatment and preventive strategies. The aim of this study was to analyse the effect of adipose-derived stem 
cells (ASC) in an experimental murine model of osteonecrosis.
Material and Methods: 38 Wistar rats were injected intraperitoneally with zoledronic acid. After treatment, upper 
jaw molars were extracted. The animals were randomly assigned to one of two groups. In the control group, saline 
solution was applied over the alveolar sockets after the tooth extractions. In the treatment group, ASCs were ap-
plied instead of saline solution. The control and treatment groups were subdivided based on the time of euthanasia. 
A clinical and histological analysis was performed.
Results: The presence of osteonecrosis in alveolar bone was observed in a similar distribution in both groups. In 
the ASC-treated group, new bone formation was greater than in controls.
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Introduction
Medication-related osteonecrosis of the jaw (MRONJ) 
is a painful condition that severely affects quality 
of life. The main drugs associated with MRONJ are 
bisphosphonates (BPs), which are antiresorptive drugs 
used to treat many diseases and conditions of increased 
bone resorption such as osteoporosis, Paget’s disease, 
multiple myeloma, hypercalcaemia of malignancy or 
osteolytic bone metastases, among others.
Osteonecrosis of the jaw is a pathological condition of 
increasing frequency with a poorly understood patho-
physiology. Despite all of the studies and advances 
achieved, MRONJ still lacks effective treatment and 
preventive strategies. The main hypotheses regarding 
the pathophysiology of osteonecrosis are pharmacologi-
cal inhibition of bone remodelling and angiogenesis, the 
presence of trauma and/or inflammation/infection, soft 
tissue BP toxicity, and an innate or acquired immune 
dysfunction(1,2).  Given the variety of hypotheses, there 
are many treatments but none is totally successful. Due 
to the lack of curative treatment for MRONJ, one of the 
best strategies nowadays is to avoid it.
Mesenchymal stem cells (MSC) have recently been 
studied for the treatment of MRONJ, and they appear 
to be beneficial for this issue. However, there are few 
published studies. Some are case reports and most use 
MSCs isolated from bone marrow (BM-MSC) (3-9). 
Studies on prevention of MRONJ and stem cells are 
emerging (4,10,11) but they are scarce, and this field 
needs to be investigated.
Adipose tissue is an abundant and easily accessible 
source of MSCs, known as adipose-derived stem cells 
(ASCs). The capacity of ASCs to promote angiogenesis, 
secrete growth factors, regulate the inflammatory pro-
cess, and differentiate into multiple cell types makes 
them a potentially ideal therapy for chronic wounds 
(12). These properties make ASCs very attractive as a 
possible tool for prevention of MRONJ.
The aim of this study was to analyse the potential effect 
of ASCs in an experimental murine model of BRONJ 
(bisphosphonate-related osteonecrosis of the jaw)-like 
disease induced with zoledronic acid (ZA) after tooth 




Currently, there is no standard MRONJ animal model. 
Conclusions: In this study, application of ASCs showed greater new bone formation in an osteonecrosis-like murine 
model. Previous inhibited post-extraction bone remodelling could be reactivated, and these findings appeared to be 
secondary to implantation of ASCs.
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A previously published MRONJ-like disease model(13) 
has been followed with some variations. The present 
study was approved by the Ethics Committee for Ani-
mal Care of La Paz University Hospital, Madrid, Spain 
(CEI 69-1212-A131).
Thirty-eight Wistar female and two male rats (Charles 
River, France) with an average age of 8 weeks and an 
average weight of 275 grams were used. All the animals 
were kept in a controlled-temperature environment 
with food and water ad libitum.
All the female animals were injected intraperitoneally 
with zoledronic acid (ZA) (Sandoz, 4 mg/100 ml) at 
dosages of 0.1 mg ZA/kg three times per week for 9 
weeks. The males received no treatment, they were used 
just to obtain adipose tissue. After this treatment, three 
right upper molars were extracted from all the animals 
under general anaesthesia with the objective of estab-
lishing the osteonecrosis model.
The molars were extracted with under optical micro-
scope assistance. After syndesmotomy with a spatula, 
the molars were luxated with a spatulated osteotrim-
mer and a mosquito clamp was used as forceps (Fig. 
1A). Surgical milling of the alveolar bone was carried 
out with a tungsten bur without irrigation to add more 
trauma.
The animals were randomly assigned to one of two 
groups. In the control group, saline solution was applied 
over the alveolar sockets after the tooth extractions. In 
the treatment group, ASCs were applied instead of sa-
line solution (one million allogeneic cells in 25 micro-
litres of Ringer’s lactate solution in each maxilla). An 
absorbable haemostatic gelatine sponge (Spongostan®) 
was used as a carrier for ASCs or for saline solution in 
each group (Fig. 1B). An advanced buccal mucoperios-
teal flap to cover the alveolar bone post-extraction was 
performed for all the animals. Gingival borders were 
attached with a continuous suture covering the defect 
without tension (Fig. 1C).
After tooth extractions, the animals were decapitated 
under general anaesthesia (inhaled isoflurane with oxy-
gen 3 L/min) and the heads were harvested for histo-
logical study. The control and treatment groups were 
subdivided as follows based on the time of euthanasia:
- Group 1: 6 control rats, euthanised 1 month after tooth 
extraction;
- Group 2: 8 treatments rats, euthanised 1 month after 
tooth extraction;
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Fig. 1: A: Tooth extraction with optical microscope assistance; B: haemostatic sponge with ASCs over the alveolar sockets; C: advanced 
buccal mucoperiosteal flap.
- Group 3: 6 control rats, euthanised 2 months after 
tooth extraction;
- Group 4: 9 treatments rats, euthanised 2 months after 
tooth extraction.
Tramadol was administered once preoperatively, and 
daily subcutaneously for 3 postoperative days.
Intraperitoneal general anaesthesia (ketamine 100 mg/
kg + diazepam 8 mg/kg + atropine 0.4 mg/kg) was first 
used; however, 9 rats (all controls) died during the pro-
cedure or on the postoperative days. Isoflurane was then 
used with no further deaths until euthanasia.
-ASC preparation
Allogeneic ASCs were obtained under inhaled general 
anaesthesia from the subcutaneous abdominal and in-
guinal fat tissue of the two male Wistar rats. This pro-
cess is based on separation by centrifugation, use of 
type I collagenase and the plastic adhesion properties 
of the cells.
Fat tissue was digested with type I collagenase (0.075%; 
Gibco BRL, Paisley, Scotland, UK). The collagenase 
was then inactivated by addition of an equal volume of 
Dulbecco’s Modified Eagle Medium (DMEM; Gibco 
BRL), which contained 10% foetal bovine serum (FBS; 
Gibco BRL). The digested tissue was centrifuged at 300 
G for 10 min. After filtering through a 70-µm nylon 
mesh, the cells were cultured in DMEM (Gibco BRL) 
containing 10% FBS (Gibco BRL) and 1% penicillin-
streptomycin (Gibco BRL). The medium was changed 
to remove nonadherent cells 24 h after seeding and ev-
ery 3–4 days thereafter. When 80%–90% confluence 
was achieved, the cells were detached with 0.05% (v/v) 
trypsin-ethylenediaminetetraacetic acid (Gibco BRL) 
in phosphate-buffered saline. The subcultured cells 
were frozen until the week before their use.
-Histological analysis 
Histological features are not included in the Ameri-
can Association of Oral and Maxillofacial Surgeons’ 
definition of MRONJ in humans. However, in rats, 
this description is one of the main tools for studying 
osteonecrosis. In this study, the characteristics of osteo-
necrosis of the jaw described previously in the literature 
have been followed (14,15). Histological sections were 
stained with haematoxylin-eosin, periodic acid-Schiff 
and Masson’s trichrome and the analysis was performed 
by two pathologists in a blinded fashion (light micros-
copy, 40x magnification). The parameters evaluated 
were as follows:
1. Osteonecrosis: defined as a portion of bone in which 
greater than or equal to 10 adjacent empty osteocyte la-
cunae are present, as previously described by Yamashi-
ta et al. (16), in 3 different random cuts (20x). 
2.  Osteoclast count: Arithmetic mean of the count in 
three different fields (40x), in two different random cuts 
in the alveolar process of the upper jaw.
3. Vascularisation: graded by a visual scale from 1 to 
5 (1: absence of vessels; 5: duplication of the vascular 
surface area compared with this area in the controls).
4. Degree of alveolar remodelling (after tooth extrac-
tion): A scale was established from 0 to 4 (0: absence 
of bone resorption; 1: < 25%; 2: 25-50%; 3: 50-75%; 4: 
75-100% of alveolar bone area resorbed and substituted 
by fibrous tissue).
5. Bone neoformation: New bone formation graded on 
a scale from 0 to 4 (0: absence of bone formation; 1: < 
25%; 2: 25-50%; 3: 50-75%; 4: 75-100% of bone forma-
tion).
6. Inflammatory infiltrates: Evaluated as presence or 
absence.
-Statistical analysis
The data analyses were performed with SPSS v. 20. A 
statistical significance level of p<.05 was used.
The quantitative variables were analysed with the non-
parametric Kruskal–Wallis test or the Mann–Whitney 
U test if necessary.
The qualitative variables were analysed with the χ2 test 
or Fisher’s exact test (if N<20 or if any expected value 
is less than 5). When the χ2 test was used, Yates’s cor-
rection was applied.
Results 
None of the animals had exposed bone at the extraction 
sites. 
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-ASCs versus controls 
When all the ASC-treated rats (groups 2 and 4) and all 
the control rats (groups 1 and 3) were compared (Table 
1), all showed the presence of osteonecrosis in alveolar 
bone in a similar distribution.
In the ASC-treated group, new bone formation was 
statistically significantly greater (with a mean value of 
3.00 in the treatment group vs. 2.18 in the control group; 
p=0.044) (Figs. 2-4).
 











































Table 1: ASC versus control rats results.
Vascularisation showed a greater mean value in the 
ASC-treated rats compared with the control group with-
out reaching statistical significance.
No differences were observed in the remaining vari-
ables (inflammatory infiltrates, osteoclast count and 
bone remodelling). 
-ASC vs. control rats euthanised 1 month after tooth 
extraction
Differences in groups 1 and 2 (treated and control rats 
Fig. 2: Histologic image of extraction sockets 
(haematoxylin-eosin, 4x). Control specimen 
(group 1). Little bone neoformation is observed.
Fig. 3: Histologic image of extraction sockets (hae-
matoxylin-eosin, 4x). ASC-treated specimen (group 
2). Greater new bone formation is observed in the 
treated specimen.
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Fig. 4: Histologic image of osteonecrosis (haematoxylin-eosin, 40x). 
Control specimen (group 1).  Empty osteocyte lacunae are observed.
euthanised 1 month after dental extractions) were ana-
lysed (Table 2).
Vascularisation and bone formation had greater mean 
values in the ASC-treated rats than in the control group, 
though statistical significance was not reached.
No statistically significant differences were found in 
osteonecrosis, osteoclasts, bone remodelling or inflam-
matory infiltrates.
-ASC vs. control rats euthanised 2 months after dental 
extraction
Vascularisation and bone formation showed greater 
mean values in the ASC-treated rats versus the control 
group, though without reaching statistical significance 
(Table 3).
Osteoclast numbers were greater in group 4 than in 
group 3, with a tendency towards statistical signifi-
cance.
 



































Table 2: ASC versus control rats euthanised 1 month after tooth extraction.
No statistically significant differences were found in 
osteonecrosis, bone remodelling or inflammatory infil-
trates.
Discussion 
Currently, there is no standard BRONJ animal model 
due to a high degree heterogeneity of models (BP type, 
dosage, concomitant treatments…). In this study, osteo-
necrosis was induced after chronic administration of 
ZA, based on previous results(13) without other drugs 
to evaluate the real effect of BP treatment, with tooth 
extraction being the trigger for BRONJ-like lesions. 
As prevention strategies are essential in MRONJ, the 
potential preventive effect of locally applied ASCs on 
bone remodelling and regeneration of tooth extraction 
sockets has been evaluated. 
None of the animals showed macroscopic bone exposure 
at the extraction sites. It is important to note that the un-
exposed bone stage of MRONJ (stage 0) in the AAOMS 
classification for humans, defined as clinical and radio-
logical findings without bone exposure, nowadays ap-
pears to be a recognized stage (1). Despite the absence 
of bone exposure, histological features of osteonecrosis 
have been observed. When all the ASC-treated rats and 
all the control rats were compared, the presence of emp-
ty lacunae in alveolar bone was observed in a similar 
distribution. Osteonecrosis is similarly in both groups 
(in 66.7% of the specimens in the ASC group and 63.3% 
in the control group). Other authors such as Kobayashi 
et al. (17) didn’t observe bone exposure either. In their 
murine model, 250 µg/Kg/day of ZA was injected from 
7 days before tooth extraction to 4 days after extrac-
tion. Although no macroscopic changes were observed 
in Kobayashi ś model, new bone formation in the tooth 
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Table 3: ASC versus control rats euthanised 2 months after tooth extraction.
extraction socket was suppressed in mice treated with 
ZA. Matsumoto et al. (18) observed a deficiency of 
bone formation and remodelling but no bone exposure 
in aged rats with a more prolonged but inferior dose of 
ZA (0.035 mg/kg every 15 days).
Alveolar coverage with a mucoperiosteal flap, surgical 
milling of alveolar bone, the high regeneration capacity 
of the rat gingiva and the lack of other osteonecrosis 
enhancer drugs could have contributed to the absence 
of macroscopic bone exposure.
It was necessary to cover the alveolar sockets with a 
mucoperiosteal flap to contain the cells, and this step 
could have promoted healing, prevented contamination 
and decreased the risk of bone exposure. Lody et al. 
(19) and Heufelder et al. (20) recommend this measure 
in their protocols to prevent development of BRONJ af-
ter tooth extraction. Surgical milling of alveolar bone 
was carried out with a tungsten bur with the intention 
of adding more trauma. This manoeuvre possibly acted 
as an alveolectomy.  It has been suggested that alveo-
lectomy might favour complete healing of the extrac-
tion wound and decrease the risk of the occurrence of 
MRONJ(21). 
In many BRONJ-like murine models, open wounds 
with bone exposure is only observed when BP is com-
bined with corticoids (22,23) or chemotherapeutic ther-
apy(11). In the present study, only ZA was administered 
to avoid confounding factors in the outcomes. 
BPs inhibit the action of osteoclasts and induce apopto-
sis. This process leads to decreased bone resorption and 
remodelling. When osteoclastic action does not occur, 
the necessary steps for the activation of osteoblasts does 
not take place (24). An important finding in this study is 
that in the ASC-treated group, new bone formation was 
greater and statistically significant (see Table 1) and was 
always greater in the ASC subgroups independent of the 
time of evolution after tooth extraction. This discovery 
is important because it could be attributed to the effect 
of stem cells.
No differences were found in the number of osteoclasts 
when comparing both groups. However, the treated rats 
euthanised 2 months after tooth extraction showed a 
greater mean value than the control group, with a ten-
dency towards statistical significance.  This difference 
could also be due to the effect of the stem cells applied. 
The increase in bone regeneration and bone remodel-
ling could be attributed to the capacity of ASCs to dif-
ferentiate directly into multiple mesodermal cell types 
(25), as well as into cells of ectodermal and endodermal 
lineages (26,27). However, according to findings in the 
literature, it is more probable that these results were re-
lated to the paracrine effects induced by ASCs. Lee et 
al. (28) have shown that ASCs could express and secret 
various cytokines, growth factors and proteins that are 
required for bone function and remodelling like M-
CSF, RANKL, BMP-2, BMP-4, HGF.
Inhibition of angiogenesis is one of the hypotheses on 
the pathophysiology of osteonecrosis. ZA has shown 
significant antiangiogenic activity in several in vitro 
and in vivo models through a reduction in serum VEGF 
(Vascular endothelial growth factor) levels (29,30). In 
addition, it has been demonstrated that ASCs secrete 
multiple proangiogenic growth factors as VEGF(31). 
Vascularisation showed a greater mean value in the 
ASC-treated rats in all groups, though statistical sig-
nificance was not reached.
Adipose tissue has been used in this model because it is 
an abundant and easily accessible source of stem cells. 
In addition, the procedure to obtain ASCs is a safe and 
minimally invasive procedure, associated with low dis-
comfort for patients. Although BM-MSCs and ASCs 
share many properties, they also present some differ-
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ences. Some studies suggest that BM-MSCs could be 
more prone to osteogenic differentiation than ASCs in 
vitro (32,33), but other authors don’t find any differenc-
es (34,35). ASCs seems to have a higher immunomodu-
latory capacity than BM-MSCs (36,37) which could im-
prove immune dysfunction related to BPs (4,6). 
There are few reports about stem cells and MRONJ and 
most of them study the treatment effects but not the pre-
ventive effects of ASCs.
Some studies on MSCs in the treatment of this condi-
tion are the reports of Kaibuchi et al. (3), Kikuiri et al. 
(4) and Ogata et al. (5), which have shown that treat-
ment with BM-MSCs is effective for the treatment of 
osteonecrosis-like disease in murine models. ZA and 
dexamethasone had been administered in these reports 
to generate the BRONJ-like model. Li et al. (6) observed 
bone exposure with BP-only treatment in larger animals 
(minipigs), and showed new bone formation in previ-
ously necrotic areas after BM-MSC infusion. There are 
a few reports on humans with good results, but with 
a low level of evidence (7-9). All of these studies use 
MSCs isolated from bone marrow.
Stem cells have been recently investigated as a preven-
tive factor in MRONJ. Kikuiri et al. (4) showed that 
systemic infusion of BM-MSCs prevents and cures 
BRONJ-like disease in a mouse model via induction of 
peripheral tolerance. Kuroshima et al. (11) investigated 
the effects of non-cultured stromal vascular fraction 
(SFV) transplantation on tooth extraction socket heal-
ing in mice. Specimens were treated previously with 
chemotherapeutic/bisphosphonate combination therapy 
and they stated that systemic transplantation of SVF 
cells ameliorates BRONJ-like lesions by improving 
both osseous and soft tissue healing of tooth extraction 
sockets. The SVF is a heterogenous population includ-
ing endothelial cells, pericytes, fibroblasts, preadipo-
cytes, ASCs... (25,38), so they have different properties 
compared with purified ASCs. 
With the objective of eliminating possible confound-
ing factors and analysing only the effects of ASCs in 
the present study, stimulation with bone morphogenetic 
protein 2 and platelet-rich plasma have been eliminated 
from our research group’s previous model (10). In the 
present model using ASCs only, new bone formation 
was greater in the treated group, suggesting that previ-
ously inhibited post-extraction bone remodelling could 
be reactivated. There is also bone formation in the con-
trol group, but it is significantly less and since the only 
difference between groups is the implantation of ASCs, 
these findings appeared to be secondary to the effects 
of stem cells.
Further studies are needed to confirm our preliminary 
results on ASCs as a preventive strategy in MRONJ, but 
these results appear to be promising. 
Prevention strategies are essential in MRONJ and this 
field needs to be investigated. In this study, the effect 
of ASCs in an experimental murine model of osteone-
crosis was analysed and the treated group has shown 
greater new bone formation. These results are promis-
ing and establish a basis for further studies and subse-
quent clinical trials in humans on the effect of ASCs as 
a preventive factor for this pathology.
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